About Mersana Therapeutics, Inc. Common Stock
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Market Cap
$0.05B
Employees
102
Listed Since
June 28, 2017
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.mersana.comPhone
617-498-0020
Headquarters
840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
CIK
0001442836